A Single-Arm, Open-Label, Multicenter Clinical Trial With Anlotinib Hydrochloride Capsule for Primary Malignant Bone Tumors With Recurrence and Distant Metastases
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs Anlotinib (Primary)
- Indications Bone cancer; Chondrosarcoma; Ewing's sarcoma; Giant cell tumours; Malignant fibrous histiocytoma; Osteosarcoma; Primitive neuroectodermal tumours
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 20 May 2019 Planned End Date changed from 31 Oct 2018 to 31 Dec 2019.
- 20 May 2019 Planned primary completion date changed from 31 Oct 2018 to 31 Dec 2019.
- 20 May 2019 Status changed from not yet recruiting to active, no longer recruiting.